^
    10ms
    A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors (ESMO 2023)
    Table: 1054P Overview of clinical and biomarker results for each individual patient Conclusions IBI345 demonstrated a manageable safety profile and preliminary efficacy in patients with CLDN18.2+ advanced solid tumors. To realize the full potential of this modular CAR-T cell product, the dose and regimen of the P329G Ab and CAR-T cells requires further exploration.
    Clinical • P1 data • PK/PD data • IO biomarker
    |
    CLDN18 (Claudin 18)
    |
    IBI-345
    12ms
    Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 (clinicaltrials.gov)
    P1, N=7, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | N=30 --> 7 | Trial completion date: Dec 2023 --> Jan 2023 | Trial primary completion date: Dec 2023 --> Oct 2022
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    IBI-345
    over2years
    Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 (clinicaltrials.gov)
    P1, N=30, Recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    IBI-345